Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2025, Vol. 30 ›› Issue (1): 91-99.doi: 10.12092/j.issn.1009-2501.2025.01.011

Previous Articles     Next Articles

Current clinical application and research progress of antiplatelet drugs

PAN Guanxing1,5, HUANG Pinfang2,5, CHAI Dajun3,5, ZHANG Jing4,5   

  1. 1 Clinical Pharmacology Research Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, Fujian, China; 2 Department of Pharmacy, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, Fujian, China; 3 Department of Cardiology, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, Fujian, China; 4 Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai 200040, China; 5 Clinical Pharmacology Research Center, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350212, Fujian, China
  • Received:2024-03-15 Revised:2024-04-17 Online:2025-01-26 Published:2025-01-02

Abstract:

Arterial thrombosis is a major cause of death in several cardiovascular diseases (CVDs), including coronary heart disease and stroke. Since platelets play a pivotal role in arterial thrombosis, antiplatelet drug is an important part of the clinical therapy of CVD patients. Currently, the long-term antithrombotic effect of the dual antiplatelet therapy of P2Y12 antagonists combined with aspirin are showed to be effective. And αΙIbβ3 antagonists represented by tirofiban are widely used for antiplatelet therapy in emergency surgery. However, the bleeding risk caused by antiplatelet therapy is a clinical issue that cannot be ignored. In order to provide a reference for further research on antiplatelet drugs, this article reviews the major targets of antiplatelet drugs and the drugs that have been under clinical research in recent years.

Key words: antiplatelet drug, platelet receptor, drug development, clinical trial

CLC Number: